Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

Abstract

Of these elderly symptomatic patients with HRPC, half had received previous chemotherapy. Weekly docetaxel was found to be associated with improvements in clinical benefit response and in QOL and was well tolerated.